Advertisement

Journal of Neuro-Oncology

, Volume 120, Issue 3, pp 547–555 | Cite as

Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France

  • Amélie Darlix
  • Sonia Zouaoui
  • Jean-Marc Virion
  • Valérie Rigau
  • Hélène Mathieu-Daudé
  • Marie Blonski
  • German Reyes-Botero
  • Faiza Bessaoud
  • Brigitte Trétarre
  • Fabienne Bauchet
  • Laurent Capelle
  • Michel Fabbro
  • Christine Kerr
  • Dominique Figarella-Branger
  • Hugues Duffau
  • Luc Taillandier
  • Luc Bauchet
Clinical Study

Abstract

Diffuse WHO grade II and III gliomas (DGII/IIIG) are rare tumors, with few specific epidemiological studies. We aimed at describing the geographical distribution of a homogeneous series of histologically confirmed DGII/IIIG, over a four-year period (2006–2009), at a national level. The methodology is based on a multidisciplinary national network already established by the French Brain Tumor DataBase and data collected directly from every neuropathology department. Personal home addresses were collected for confirmed cases. For each region, the incidence of DGII/IIIG was analyzed and standardized on the age and sex distribution of the French population. The number of patients with newly diagnosed, histologically confirmed DGII/IIIG was 4,790. The overall crude rate was 19.4/106. To enable international comparisons, standardized rates were calculated as follows: 19.8/106, 18.8/106 and 16.0/106 (reference population, Europe, US and world, respectively). The geographical distribution by region showed significant differences, with higher incidence rates in Northeast and central parts of France. This work is the first studying the geographical distribution of a pure series of DGII/IIIG at a national level. It demonstrates significant heterogeneity in the distribution, and raises the question of the role of environmental and/or genetic risk(s) factor(s) for DGII/IIIG.

Keywords

Brain tumor Neurooncology Glioma Epidemiology 

Notes

Acknowledgments

The authors wish to thank all pathologists, neurosurgeons and other stakeholders, for their help and input with this work (see the list in supplementary materials), and Bénédicte Clément, scientific translator, for valuable translation work. This work was conducted with the financial support in the form of grants from the Ligue Nationale Contre le Cancer, Association des Neuro-Oncologues d’Expression Française, Société Française de Neurochirurgie, Associations pour la Recherche sur les Tumeurs Cérébrales (ARTC and ARTC Sud), Roche Laboratory, Sophysa Laboratory, Département de l’Hérault, and Groupe de Neuro-Oncologie du Languedoc Roussillon.

Conflict of interest

None declared.

Supplementary material

11060_2014_1585_MOESM1_ESM.tif (6 mb)
Supplementary material 1 (TIFF 6184 kb)
11060_2014_1585_MOESM2_ESM.tif (6 mb)
Supplementary material 2 (TIFF 6189 kb)
11060_2014_1585_MOESM3_ESM.doc (44 kb)
Supplementary material 3 (DOC 44 kb)
11060_2014_1585_MOESM4_ESM.doc (106 kb)
Supplementary material 4 (DOC 111 kb)
11060_2014_1585_MOESM5_ESM.doc (106 kb)
Supplementary material 5 (DOC 104 kb)
11060_2014_1585_MOESM6_ESM.doc (106 kb)
Supplementary material 6 (DOC 104 kb)

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14(suppl 5):v1–v49PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109:93–108PubMedCrossRefGoogle Scholar
  4. 4.
    Wöhrer A, Waldhör T, Heinzl H et al (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95:401–411PubMedCrossRefGoogle Scholar
  5. 5.
    Baldi I, Gruber A, Alioum A et al (2011) Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. Neuro Oncol 13:1370–1378PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Ron E, Modan B, Boice JD, Alfandary E, Stovall M, Katz L (1988) Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 319:1033–1039PubMedCrossRefGoogle Scholar
  7. 7.
    Yonehara S, Brenner AV, Kishikawa M et al (2004) Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958-1995. Cancer 101:1644–1654PubMedCrossRefGoogle Scholar
  8. 8.
    Bondy ML, Scheurer ME, Malmer B et al (2008) Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113(7 Suppl):1953–1968PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    McCarthy BJ, Rankin KM, Aldape K et al (2011) Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol 13:242–250PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Crocetti E, Trama A, Stiller C et al (2012) Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 48:1532–1542PubMedCrossRefGoogle Scholar
  11. 11.
    Houben MP, Coebergh JW, Birch JM, Tijssen CC, van Duijn CM, McNally RJ (2005) Space–time clustering patterns of gliomas in the Netherlands suggest an infectious aetiology. Eur J Cancer 41:2917–2923PubMedCrossRefGoogle Scholar
  12. 12.
    Houben MP, Coebergh JW, Birch JM, Tijssen CC, van Duijn CM, McNally RJ (2006) Space-time clustering of glioma cannot be attributed to specific histological subgroups. Eur J Epidemiol 21:197–201PubMedCrossRefGoogle Scholar
  13. 13.
    Bauchet L, Rigau V, Mathieu-Daudé H et al (2007) French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol 84:189–199PubMedCrossRefGoogle Scholar
  14. 14.
    Bauchet L, Rigau V, Mathieu-Daudé H et al (2009) Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol 92:87–98PubMedCrossRefGoogle Scholar
  15. 15.
    Bauchet L, Mathieu-Daudé H, Fabbro-Peray P et al (2010) Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 12:725–735PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Rigau V, Zouaoui S, Mathieu-Daudé H et al (2012) French brain tumor database: 5- year histological results on 25756 cases. Brain Pathol 21:633–644CrossRefGoogle Scholar
  17. 17.
    Zouaoui S, Rigau V, Mathieu-Daudé H et al (2012) French brain tumor database: general results on 40,000 cases, main current applications and future prospects. Neurochirurgie 58:4–13PubMedCrossRefGoogle Scholar
  18. 18.
    Hartmann C, von Deimling A (2009) Molecular pathology of oligodendroglial tumors. Recent Results Cancer Res 171:25–49PubMedCrossRefGoogle Scholar
  19. 19.
    van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120(3):297–304PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Davis FG, Malmer BS, Aldape K et al (2008) Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 17(3):484–489PubMedCrossRefGoogle Scholar
  21. 21.
    Okamoto Y, Di Patre P-L, Burkhard C, Horstmann S, Jourde B, Fahey M et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56PubMedCrossRefGoogle Scholar
  22. 22.
    Arora RS, Alston RD, Eden TO et al (2010) Are reported increases in incidence of primary CNS tumours real ? An analysis of longitudinal trends in England, 1979-2003. Eur J Cancer 46:1607–1616PubMedCrossRefGoogle Scholar
  23. 23.
    Chan DS, Lau R, Aune D et al (2011) Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS One 6(6):e20456PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Aleksandrova K, Nimptsch K, Pischon T (2013) Influence of obesity and related metabolic alterations on colorectal cancer risk. Curr Nutr Rep 2(1):1–9PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Boeing H, Schlehofer B, Blettner M, Wahrendorf J (1993) Dietary carcinogens and the risk for glioma and meningioma in Germany. Int J Cancer 53(4):561–565PubMedCrossRefGoogle Scholar
  26. 26.
    Blowers L, Preston-Martin S, Mack WJ (1997) Dietary and other lifestyle factors of women with brain gliomas in Los Angeles County (California, USA). Cancer Causes Control 8:5–12PubMedCrossRefGoogle Scholar
  27. 27.
    Kyritsis AP, Bondy ML, Levin VA (2011) Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents. Nutr Cancer 63(2):174–184PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Huncharek M, Kupelnick B, Wheeler L (2003) Dietary cured meat and the risk of adult glioma: a meta-analysis of nine observational studies. J Environ Pathol Toxicol Oncol 22(2):129–137PubMedGoogle Scholar
  29. 29.
    Michaud DS, Holick CN, Batchelor TT, Giovannucci E, Hunter DJ (2009) Prospective study of meat intake and dietary nitrates, nitrites, and nitrosamines and risk of adult glioma. Am J Clin Nutr 90:570–577PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Dubrow R, Daresky AS, Park Y et al (2010) Dietary components related to N-Nitroso compound formation: a prospective study of adult glioma. Cancer Epidemiol Biomarkers Prev 19(7):1709–1722PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Fromont A, Binquet C, Sauleau EA et al (2010) Geographic variations of multiple sclerosis in France. Brain 133:1889–1899PubMedCrossRefGoogle Scholar
  32. 32.
    Fromont A, Binquet C, Sauleau E et al (2012) National estimate of multiple sclerosis incidence in France (2001-2007). Mult Scler 18(8):1108–1115PubMedCrossRefGoogle Scholar
  33. 33.
    Vukusic S, Van Bockstael V, Gosselin S, Confavreux C (2006) Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry 78:707–709CrossRefGoogle Scholar
  34. 34.
    Ebers GC (2008) Environmental factors and multiple sclerosis. Lancet Neurol 7(3):268–277PubMedCrossRefGoogle Scholar
  35. 35.
    Kampman MT, Wilsgaard T, Mellgren SI (2007) Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 254(4):471–477PubMedCrossRefGoogle Scholar
  36. 36.
    Mohr SB, Gorham ED, Garland CF, Grant WB, Garland FC (2010) Low ultraviolet B and increased risk of brain cancer: an ecological study of 175 countries. Neuroepidemiology 35(4):281–290PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Amélie Darlix
    • 1
    • 2
  • Sonia Zouaoui
    • 2
    • 3
    • 4
  • Jean-Marc Virion
    • 5
  • Valérie Rigau
    • 6
  • Hélène Mathieu-Daudé
    • 4
  • Marie Blonski
    • 7
  • German Reyes-Botero
    • 8
  • Faiza Bessaoud
    • 4
  • Brigitte Trétarre
    • 4
  • Fabienne Bauchet
    • 4
  • Laurent Capelle
    • 9
  • Michel Fabbro
    • 1
  • Christine Kerr
    • 1
  • Dominique Figarella-Branger
    • 10
  • Hugues Duffau
    • 2
    • 3
  • Luc Taillandier
    • 11
  • Luc Bauchet
    • 2
    • 3
  1. 1.Departement of Medical Oncology and Department of Radiation OncologyInstitut Régional du Cancer de Montpellier - Val d’AurelleMontpellierFrance
  2. 2.INSERM U1051MontpellierFrance
  3. 3.Department of NeurosurgeryGui de Chauliac HospitalMontpellierFrance
  4. 4.Department of Epidemiology, French Brain Tumor Database, GNOLR, Registre des Tumeurs de l’HéraultInstitut Régional du Cancer de Montpellier - Val d’AurelleMontpellierFrance
  5. 5.Department of Clinical Epidemiology and EvaluationUniversity HospitalNancyFrance
  6. 6.Department of PathologyGui de Chauliac HospitalMontpellierFrance
  7. 7.Neuro-oncology UnitCentral HospitalNancyFrance
  8. 8.Department of NeurologyPitié-Salpétrière HospitalParisFrance
  9. 9.Department of NeurosurgeryPitié-Salpétrière HospitalParisFrance
  10. 10.Department of Neuropathology and INSERM U911, Timone HospitalUniversité de la MéditerranéeMarseilleFrance
  11. 11.Neuro-oncology UnitUniversity HospitalPoitiersFrance

Personalised recommendations